Research programme: GPR91 antagonists - Advinus Theraeputics

Drug Profile

Research programme: GPR91 antagonists - Advinus Theraeputics

Latest Information Update: 24 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advinus Therapeutics
  • Class Antifibrotics; Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Eye disorders; Liver disorders

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis
  • Research Liver disorders; Retinal disorders

Most Recent Events

  • 11 Nov 2016 Preclinical trials in non-alcoholic steatohepatitis in India before November 2016
  • 21 Jan 2016 Research programme: GPR91 antagonists - Advinus Theraeputics is available for licensing as of 21 Jan 2016. www.advinus.com
  • 21 Jan 2016 Early research in Liver disorders in India (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top